Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Howard, Lien"'
Autor:
Y Howard Lien, Megan B Dixon
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 6, Pp 1149-1155 (2008)
Megan B Dixon, Y Howard LienDepartment of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USAAbstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water
Externí odkaz:
https://doaj.org/article/11369457b5934c759fae49bb968ddbc0
Autor:
Chevalia Robinson, Y. Howard Lien, Roscoe O. Brady, Bradley L. Schlaggar, Gregory M. Pastores, Margaret Timmons, Markus Ries, Michael Beck, Joe T.R. Clarke, Raphael Schiffmann, Christoph Kampmann, Catharina Whybra
Publikováno v:
Pediatrics. 118:924-932
CONTEXT. Fabry disease is an X-linked multisystem disorder. Enzyme-replacement therapy in adults has limited efficacy in treating major sequelae of advanced Fabry disease, such as kidney failure or stroke. This prompted a study of the safety and effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45ee9db686babb08b138c19d4665b9e
https://doi.org/10.1542/peds.2005-2895
https://doi.org/10.1542/peds.2005-2895
Autor:
Todd Purves, Hardeep Phull, Joel Funk, Sanjay Ramakumar, Yeong Hau Howard Lien, Judith B. Ulreich, Duan C. Copeland, Li Wen Lai
Publikováno v:
Journal of Urology. 174:1133-1136
Ischemia/reperfusion injury is a leading cause of renal damage and antisense gene therapy has been shown to ameliorate its effects. However, this approach has been limited by current delivery methods that require high concentrations of intravenous nu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea14572b20ca79044ef658ab8184ae53
https://doi.org/10.1097/01.ju.0000168617.17080.46
https://doi.org/10.1097/01.ju.0000168617.17080.46
Publikováno v:
The American Journal of Medicine. 120:e7-e9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c4d3d9bd015a47f90cef4d93bd6802
https://doi.org/10.1016/j.amjmed.2005.09.041
https://doi.org/10.1016/j.amjmed.2005.09.041
Autor:
Y Howard Lien, Megan B Dixon
Publikováno v:
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 6, Pp 1149-1155 (2008)
Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 6, Pp 1149-1155 (2008)
Megan B Dixon, Y Howard LienDepartment of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USAAbstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efca49716e4d914c65e336c7b6f72c05
https://pubmed.ncbi.nlm.nih.gov/19337422
https://pubmed.ncbi.nlm.nih.gov/19337422
Autor:
Yeong-Hau Howard Lien
Publikováno v:
The American journal of medicine. 121(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa20fb5ae5073349a130d42d19918465
https://pubmed.ncbi.nlm.nih.gov/18954834
https://pubmed.ncbi.nlm.nih.gov/18954834
Publikováno v:
Echocardiography (Mount Kisco, N.Y.). 25(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::acae3895f02b303a9460daf027c87c32
https://pubmed.ncbi.nlm.nih.gov/18177384
https://pubmed.ncbi.nlm.nih.gov/18177384
Autor:
Laura C. McCary, Chaim Charytan, Jack W. Coburn, Wei Liu, Y. Howard Lien, James Herman, Preston S. Klassen, Michel Chonchol, Vincent Pichette
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 46(1)
Secondary hyperparathyroidism develops early in patients with chronic kidney disease (CKD). Clinical guidelines from the National Kidney Foundation-Kidney/Disease Outcomes Quality Initiative emphasize the need to control parathyroid hormone (PTH), ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01163690ef80f91c1ab26faffec874da
https://pubmed.ncbi.nlm.nih.gov/16377407
https://pubmed.ncbi.nlm.nih.gov/16377407
Autor:
Markus Ries, Rick A. Martin, Tyler Reimschisel, Christoph Kampmann, Victoria Castaneda, Karen C. Johnson, Y. Howard Lien, Joe T.R. Clarke, Raphael Schiffmann, Gregory M. Pastores
Publikováno v:
The Journal of Pediatrics. 156:832-837.e1
To investigate a 4-year prospective clinical trial of agalsidase alfa in children with Fabry disease, an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A.Seventeen (16 boys, 1 girl; age range, 7.3 to 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d952561d2abf69cbcb356089ab1c3d6
https://doi.org/10.1016/j.jpeds.2009.11.007
https://doi.org/10.1016/j.jpeds.2009.11.007
Autor:
Nathalie Guffon, Dominique P. Germain, Ashok Vellodi, Michel Tsimaratos, Anna Tylki-Szymańska, J. Edmond Wraith, Y. Howard Lien
Publikováno v:
The Journal of Pediatrics. 152:563-570.e1
Objective To evaluate the safety and explore the efficacy of enzyme replacement therapy with agalsidase beta (recombinant human α-galactosidase A; Fabrazyme [Genzyme Corporation, Cambridge, MA]) in pediatric patients with Fabry disease, a genetic di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197b38ef4ac92013ccf04005e8de8f69
https://doi.org/10.1016/j.jpeds.2007.09.007
https://doi.org/10.1016/j.jpeds.2007.09.007